How is diroximel fumarate thought to exert its therapeutic effects in multiple sclerosis?

Diroximel fumarate’s mechanism in multiple sclerosis is not fully understood, but it acts through its major active metabolite, monomethyl fumarate, whose pharmacodynamic responses appear, in preclinical studies, to be mediated at least partly through activation of the Nrf2 transcriptional pathway.